Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL36994 | 0.92 | ALDH1A1 (0.37) | ALDH1A1L3MBTL1MEN1KMT2AGAA | |
| SCHEMBL46115 | 0.89 | ALDH1A1 (0.40) | ALDH1A1L3MBTL1MEN1KMT2AGAA | |
| SCHEMBL14998146 | 0.86 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1MEN1KMT2AGAA | |
| SCHEMBL14834128 | 0.81 | OPRM1 (0.33) | MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL14834149 | 0.81 | OPRM1 (0.31) | MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL15423018 | 0.81 | POLB (0.36) | ALDH1A1L3MBTL1MEN1KMT2AOPRM1 | |
| SCHEMBL19956388 | 0.80 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1MEN1KMT2AGAA | |
| SCHEMBL46189 | 0.78 | MEN1 (0.34) | ALDH1A1L3MBTL1MEN1KMT2AGAA | |
| SCHEMBL46282 | 0.78 | EPHX2 (0.34) | ALDH1A1L3MBTL1MEN1KMT2AGAA | |
| SCHEMBL46187 | 0.78 | OPRM1 (0.32) | ALDH1A1L3MBTL1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210625-A1 | SPIROHETEROCYCLIC PYRROLIDINE DERIVATIVES BASED PESTICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210625-A1 | SPIROHETEROCYCLIC PYRROLIDINE DERIVATIVES BASED PESTICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210625-A1 | SPIROHETEROCYCLIC PYRROLIDINE DERIVATIVES BASED PESTICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2013079672-A1 | HERBICIDAL USES OF SUBSTITUTED SPIROHETEROCYCLIC PYRROLIDINE DIONE DERIVATIVES, AND HERBICIDAL COMPOSITIONS COMPRISING THEM | SYNGENTA LIMITED (GB) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013079672-A1 | HERBICIDAL USES OF SUBSTITUTED SPIROHETEROCYCLIC PYRROLIDINE DIONE DERIVATIVES, AND HERBICIDAL COMPOSITIONS COMPRISING THEM | SYNGENTA LIMITED (GB) | 2013-06-06 | — | — | WO | disclosed |
| EP-2576511-A1 | SPIROHETEROCYCLIC PYRROLIDINE DERIVATIVES BASED PESTICIDES | Syngenta Participations AG (CH) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011151199-A1 | SPIROHETEROCYCLIC PYRROLIDINE DERIVATIVES BASED PESTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151199-A1 | SPIROHETEROCYCLIC PYRROLIDINE DERIVATIVES BASED PESTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210625-A1 | SPIROHETEROCYCLIC PYRROLIDINE DERIVATIVES BASED PESTICIDES | DDT, PYCR1, PKD2 | ALDH1A1 341/4885L3MBTL1 2524/4885MEN1 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.